angela-grant-headshot
19 July 2022AmericasSarah Speight

Haynes Boone hires top biotech patent lawyer

New partner boosts firm’s biotech practice | Move forms part of life sciences expansion | Role based at Washington, DC office.

Angela Grant has joined Haynes Boone as a partner in the firm’s Patent Prosecution Practice.

With a PhD in immunology and microbiology, Grant brings “significant” experience advising clients in the biotechnology and life sciences sectors.

She specialises in developing and managing global patent portfolios; performing IP due diligence related to investments and acquisitions; and preparing non-infringement, invalidity, and ‘freedom to operate’ opinions.

“Angela greatly enhances our bench strength in the biotechnology sector,” said partner Jeffrey Wolfson, chair of Haynes Boone’s Patent Prosecution Practice Group.

“She has deep roots in the Boston biotech community and broad-based experience across a range of key technologies. We are thrilled to have her on board to continue our Life Sciences expansion.”

Grant moves to this role from Lathrop GPM, where she was a partner at the Boston office.

Her clients have ranged from biotech startups to venture capital firms, focused on technologies involving multispecific and multifunctional antibodies, cell therapies, gene editing, RNA therapeutics, and synthetic oligosaccharides.

She obtained her PhD from The George Washington University and was a postdoctoral research fellow at the Harvard School of Public Health. She later earned her JD cum laude from Suffolk University Law School.

“I was attracted to Haynes Boone because of the quality and depth of its patent team and its robust transactional practice,” said Grant, who will be based in Washington, DC.

“I look forward to helping Haynes Boone continue to expand its patent and technology transactions capabilities.”

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
6 October 2021   Medical device company SurgiSil has persuaded the US Court of Appeals for the Federal Circuit that its application for a design patent covering a lip filler was erroneously rejected by the US Patent and Trademark Office.
Biotechnology
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
article
9 February 2023   The patent attorneys will be based in London and Birmingham.

More on this story

Biotechnology
6 October 2021   Medical device company SurgiSil has persuaded the US Court of Appeals for the Federal Circuit that its application for a design patent covering a lip filler was erroneously rejected by the US Patent and Trademark Office.
Biotechnology
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
article
9 February 2023   The patent attorneys will be based in London and Birmingham.

More on this story

Biotechnology
6 October 2021   Medical device company SurgiSil has persuaded the US Court of Appeals for the Federal Circuit that its application for a design patent covering a lip filler was erroneously rejected by the US Patent and Trademark Office.
Biotechnology
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
article
9 February 2023   The patent attorneys will be based in London and Birmingham.